Triprolizumab

Phase 2Monoclonal antibody

SSun Yat-sen University

Triprolizumab is one of 7 small molecule programs targeting Adrenal Cortical Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adrenal Cortical CarcinomaRecruiting

Adrenal Cortical CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

6 competitors in Adrenal Cortical Carcinoma

#DrugCompanyPhaseTrials

Cabometyx

Bristol-Myers Squibb

Phase 2

2 2

Keytruda

Merck & Co.

Phase 2

1 3

Tuoyi

SSun Yat-sen University

Phase 2

1 4

Cometriq

EExelixis

Phase 2

1 5

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Phase 2

1 6

Lysodren

TTerezinha de Jesus Esteves Barata

Phase 2

1 7

Triprolizumab

SSun Yat-sen University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Adrenal Cortical Carcinoma

NCT06587802

Clinical

Trials by Indication[1]

Adrenal Cortical Carcinoma1 trial

Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT06587802·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Triprolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Triprolizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Triprolizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: SSun Yat-sen University

Triprolizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Adrenal Cortical Carcinoma1 trial

References

Drug Info

Quick Facts

Related News